New Machine Learning Program Shows Promise for Early Alzheimer's Diagnosis

저자：   업로드：2017-08-18  조회수：

    A new machine learning program developed by researchers at Case Western Reserve University appears to outperform other methods for diagnosing Alzheimer's disease before symptoms begin to interfere with every day living, initial testing shows.

    While there is no cure for Alzheimer’s, a number of drugs can delay or prevent symptoms from worsening for up to five years or more, Early diagnosis and treatment—the goal of the new computer-based program—is key to allowing those with the disease to remain independent longer, according to the researchers.

    The computer program integrates a range of Alzheimer's disease indicators, including mild cognitive impairment. In two successive stages, the algorithm selects the most pertinent to predict who has Alzheimer's.

    The team published its study (“Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features”) in Scientific Reports.

    “The introduction of mild cognitive impairment (MCI) as a diagnostic category adds to the challenges of diagnosing Alzheimer’s Disease (AD). No single marker has been proven to accurately categorize patients into their respective diagnostic groups,” write the investigators.

    “In this work, we present a combined framework, cascaded multiview canonical correlation (CaMCCo), for fusion and cascaded classification that incorporates all diagnostic categories and optimizes classification by selectively combining a subset of modalities at each level of the cascade.”

    "Many papers compare the healthy to those with the disease, but there's a continuum," said Anant Madabhushi, Ph.D., F. Alex Nason professor II of biomedical engineering at Case Western Reserve. "We deliberately included mild cognitive impairment, which can be a precursor to Alzheimers, but not always."

    The scientists tested the algorithm using data from 149 patients collected via the Alzheimer's Disease Neuroimaging Initiative. The CaMCCo integrates measurements from magnetic resonance imaging scans, features of the hippocampus, glucose metabolism rates in the brain, proteomics, genomics, mild cognitive impairment, and other parameters.

    Dr. Madabhushi's lab has repeatedly found that integrating dissimilar information

이전：Checkpoint Protein Propped Up by Cell-Surface Sidekick

다음에：Stroke, Heart Attack Damage Could Be Mitigated via Mimicry of Good Cholesterol